The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors. JTX-8064, is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage receptor Leukocyte Immunoglobulin Like Receptor B2 (LILRB2/ILT4), inhibiting LILRB2 binding with its ligands which may result in reprogramming immune-suppressive macrophages to enhance anti-tumor immunity.
A data review was conducted on
Ovarian Cancer Combination Cohort Responders
Subject | PD-L1 (CPS) | Response Assessment | When was uPR demonstrated | Current status |
1 | 55% | cPR | Wk 9 | -82.8% (wk 45) |
2 | 15% | cPR | Wk 18 | -66.4% (wk 36) |
3 | 5% | cPR | Wk 18 | -87.6% (wk 27) |
4 | 0% | cPR | Wk 18 | -78.26% (wk 27) |
5 | 0% | uPR | Wk 27 | -40% (wk 27) |
Ovarian Combination Cohort Target Lesion % Change from Baseline over Time
“Following this analysis, we are pleased to see these results demonstrating deep and durable responses in patients, including those with a PD-L1 score of 0%, on a very well tolerated regimen. These results lead us to believe that there is a potential for meaningful clinical benefit with this combination in patients with few durable therapeutic options,” said
Enrollment has been completed in all cohorts in the INNATE trial. In addition to the patients with ovarian cancer, both durable responses and stable disease have occurred in patients with renal cell carcinoma, biliary tract cancer, and first-line and second/third-line head and neck squamous cell carcinoma, but the ovarian data is the most encouraging with potential to achieve pre-determined POC criteria.
As previously announced, Jounce is seeking to partner JTX-8064. Jounce continues to believe a company with additional resources and a longer value creation timeline could potentially advance this program for the benefit of cancer patients.
About
Cautionary Note Regarding Forward-Looking Statements
Various statements in this release concerning Jounce’s future expectations, plans and prospects, including without limitation, the potential clinical benefit of JTX-8064 in combination with a PD-1 inhibitor, the likelihood of any cohort in the INNATE trial achieving proof-of-concept, and the opportunities for potential advancement of its JTX-8064 program by a third party may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as, “believe,” “potential,” or similar terms, variations of such terms or the negative of those terms. Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, whether interim results or past results from a clinical trial will be predictive of the final results of the trial or the results of future trials; Jounce’s ability to successfully demonstrate the efficacy, safety and/or potential advantages of JTX-8064; Jounce’s ability to establish and maintain a partnership on favorable terms, if at all and the success of any such partnership that Jounce enters into; Jounce’s ability to obtain, maintain and protect its intellectual property; and those risks more fully discussed in the section entitled “Risk Factors” in Jounce’s most recent Annual Report on Form 10-K filed with the
Investor and Media Contacts:
+1-857-259-3840
ir@jouncetx.com
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ad7bcbc-4f81-4322-a1cb-9be8ec391bfb
Ovarian Combination Cohort Target Lesion % Change from Baseline over Time
Ovarian Combination Cohort Target Lesion % Change from Baseline over Time
2023 GlobeNewswire, Inc., source